Company profile: Therakos
1.1 - Company Overview
Company description
- Provider of extracorporeal photopheresis immune modulation therapy to enhance immunologic response. Offers the THERAKOS CELLEX Photopheresis System used with UVADEX (methoxsalen) Sterile Solution to treat skin manifestations of CTCL, plus single-use procedural kits. Provides training via THERAKOS INSTITUTE, MyTHERAKOS portal documentation, and 24/7 customer, clinical, technical and product support.
Products and services
- Procedural Kit: Single-use procedural set containing supplies needed for one photopheresis treatment, including a photoactivation module, centrifuge bowl, treatment bag, return bag, and pump tubing
- THERAKOS CELLEX Photopheresis System: Extracorporeal device that extracts, treats, and reinfuses white blood cells to manage skin manifestations of CTCL, operated with UVADEX for cases unresponsive to other treatments
- UVADEX (methoxsalen) Sterile Solution: Sterile photosensitizing agent used alongside the CELLEX System to treat white blood cells for skin manifestations of CTCL, including cases unresponsive to other therapies
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Therakos
Evommune
HQ: United States
Website
- Description: Provider of therapeutics to halt progressive disease and address symptoms, focused on chronic inflammatory diseases. Develops EVO756, an oral, highly selective MRGPRX2 inhibitor for chronic spontaneous urticaria despite H1 antihistamines; a PKCθ inhibitor to regulate immune response; collaborative drug discovery with partners like Accutar; and clinical trial programs, including Phase 1 for EVO756.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Evommune company profile →
Viridian Therapeutics
HQ: United States
Website
- Description: Provider of treatments for patients suffering from diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Viridian Therapeutics company profile →
BioAtla
HQ: United States
Website
- Description: Provider of conditionally active biologics (CABs) for cancer-targeted therapeutics activated under specific physiological conditions; the CIAO! platform for antibody optimization; CAB-ADCs, CAB-CAR-T, and CAB-Bispecifics to improve safety and efficacy; and Mecbotamab Vedotin, a CAB-AXL-ADC for AXL-expressing tumors evaluated in sarcoma and NSCLC.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioAtla company profile →
BioXell
HQ: Italy
Website
- Description: Provider of recombinant protein expression and purification services; stable cell line generation using proprietary ExoIN technology and cGMP-compliant CHO-based platforms; transient protein expression; customized protein expression screening; high-yield recombinant protein production in E. coli, yeast, and mammalian systems; and monoclonal and polyclonal antibody development via hybridoma and phage display.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioXell company profile →
Escient Pharmaceuticals
HQ: United States
Website
- Description: Provider of bio-technical research and development services focused on advancing first-in-class G Protein-Coupled Receptor targeted drugs and therapies for neuro-immuno-inflammatory and autoreactive diseases. Pipeline includes EP262, an oral, once-daily small molecule MRGPRX2 antagonist for the potential treatment of mast cell-mediated diseases (including chronic urticarias and atopic dermatitis), and EP547, an oral, once-daily MRGPRX4 antagonist for cholestatic and uremic pruritus.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Escient Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Therakos
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Therakos
2.2 - Growth funds investing in similar companies to Therakos
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Therakos
4.2 - Public trading comparable groups for Therakos
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →